Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kansas City-based CyDex has agreed to license its Captisol enabling technology to Proteolix for use with a proteasome inhibitor that has shown promise in treating certain cancers such as multiple myeloma and mantle cell lymphoma.
Subscribe to our email newsletter
CyDex’s Captisol technology improves water solubility, bioavailability and complexation characteristics of insoluble and/or unstable drugs. CyDex has granted Proteolix global rights to Captisol for a formulation of PR-171 – a novel proteasome inhibitor derived from the natural product epoxomicin.
PR-171, also known as carfilzomib, is potent on heme tumor cell lines and induces programmed cell death in multiple myeloma cells taken from patients, including those that are resistant to current therapies. The compound is currently in phase I clinical trials at six leading oncology centers in the US and Canada.